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M A J O R A R T I C L E
Herpes Simplex Virus Type-2 Cervicovaginal Shedding
Among Women Living With HIV-1 and Receiving
Antiretroviral Therapy in Burkina Faso: An 8-Year
Longitudinal Study
Andrea J. Low,1 Nicolas Nagot,2,3 Helen A. Weiss,1 Issouf Konate,4 Dramane Kania,4 Michel Segondy,2,3 Nicolas Meda,4 Philippe van de Perre,2,3 and
Philippe Mayaud1,a; for the Yerelon Study Group
1London School of Hygiene and Tropical Medicine, United Kingdom; 2UMR 1058 University of Montpellier, 3Montpellier University Hospital, France; and 4Centre Muraz, Bobo-Dioulasso, Burkina Faso
Background. The impact of antiretroviral therapy (ART) on herpes simplex virus type-2 (HSV-2) replication is unclear. The aim
of this study was to assess factors associated with cervicovaginal HSV-2 DNA shedding and genital ulcer disease (GUD) in a cohort
of women living with human immunodeﬁciency virus type-1 (HIV-1) in Burkina Faso.
Methods. Participants were screened for cervicovaginal HSV-2 DNA, GUD, cervicovaginal and systemic HIV-1 RNA, and re-
productive tract infections every 3–6 months over 8 years. Associations with HSV-2 shedding and quantity were examined using
random-effects logistic and linear regression, respectively.
Results. Of the 236 women with data on HSV-2 shedding, 151 took ART during the study period. Cervicovaginal HSV-2 DNA
was detected in 42% of women (99 of 236) in 8.2% of visits (151 of 1848). ART was associated with a reduction in the odds of HSV-2
shedding, which declined for each year of ART use (odds ratio [OR], 0.74; 95% conﬁdence interval [CI], .59–.92). In the multivariable
model, the impact of ART was primarily associated with suppression of systemic HIV-1 RNA (adjusted OR, 0.32; 95% CI, .15–.67).
A reduction in the odds of GUD was also observed during ART, mainly in those with HIV-1 suppression (adjusted OR, 0.53; 95% CI,
.25–1.11).
Conclusions. ART is strongly associated with a decrease in cervicovaginal HSV-2 shedding, and the impact was sustained over
several years.
Keywords. antiretrovirals; HIV-1; herpes simplex virus type-2; HSV-2; female; genital tract; genital ulcer disease; Burkina Faso.
Herpes simplex virus type 2 (HSV-2) infection is one of the
most common sexually transmitted infections, with the highest
burden in Africa [1]. HSV-2 coinfection is associated with in-
creased plasma and genital human immunodeﬁciency virus
type 1 (HIV-1) loads [2, 3] and increased quantities of genital
tract inﬂammatory cells [4, 5]. People living with HIV tend to
have more-frequent HSV-2 clinical manifestations, with recur-
rent and persistent genital ulcerative disease (GUD) attributed
to impaired immune responses [6, 7]. HIV coinfection has also
been shown to increase genital shedding of HSV-2 [8] and the
likelihood of transmission [9].
Antiretroviral therapy (ART) should reduce clinical and
asymptomatic manifestations of HSV-2 infection, through
immune restoration. The impact of antiretroviral therapy (ART)
on GUD and HSV-2 shedding has been described in multiple
contexts, with varying results depending on sampling frequency
[10, 11]. Both GUD and HSV-2 genital shedding can increase
during the ﬁrst 1–3 months of ART, particularly among women
with low CD4+ T-cell counts at ART initiation, likely owing to
immune reconstitution [12, 13]. The impact of ART on HSV-2
shedding beyond 6 months has not been described.
In this article, we present data on the short-term and long-
term effects of ART on symptomatic HSV-2 genital shedding
(deﬁned as the presence of GUD) and asymptomatic HSV-2
genital shedding in a cohort of high-risk women living with
HIV-1 in Burkina Faso.
METHODS
Participants were women living with HIV-1 and coinfected with
HSV-2 who were enrolled in the Yerelon cohort in Bobo-
Dioulasso, Burkina Faso [14–16]. Combined ART has been
available since 2004 for women with World Health Organization
clinical stage 3/4 HIV disease or a CD4+ T-cell count of ≤200
cells/µL (or ≤350 cells/µL, beginning in 2009) [17]. First-line
treatment for most participants was based on nonnucleoside
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reverse transcriptase inhibitors. Participants were followed ap-
proximately every 3–6 months. A subset of women were enrolled
in a randomized trial of valacyclovir to suppress HIV-1 genital
shedding, with fortnightly visits over a 12-week period in 2004–
2005 [18,19]. All visits corresponding to regular cohort visits were
included in this analysis, excluding those with valacyclovir use.
At each visit, a clinician performed a gynecological examina-
tion; recorded whether GUD was present, based on detection of
vesicles or ulcers; and collected genital samples. Enriched cervico-
vaginal lavage (eCVL) was performed by infusing 2 mL of normal
saline into the vagina for 60 seconds and collecting it into a cry-
otube. A swab was rotated 360 degrees in the cervical os and
placed into the same cryotube [20]. Women with symptoms of
reproductive tract infections were treated according to national
syndromic management guidelines, which did not include acyclo-
vir during the study period. Visits were deferred during menses.
The research protocol was approved by the institutional re-
view boards at the London School of Hygiene and Tropical
Medicine and Centre Muraz and the research ethics committee
at the Burkina Faso Ministry of Health. All women provided
written informed consent.
HSV-2 serology was assessed using the Kalon IgG2-ELISA kit
(Kalon Biologicals). HIV-1 RNA in plasma and eCVL specimens
was detected and quantiﬁed using real-time polymerase chain re-
action (PCR) analysis (Generic HIV Viral Load; Biocentric) [21].
HSV-2 DNA was extracted from 200 µL of eCVL ﬂuid by using
the QIAamp DNAmini kit (Qiagen) and was eluted in 100 µL of
buffer. HSV-2 DNA was ampliﬁed from 5 µL of eluate by Taq-
Man real-time PCR analysis, using the ABI Prism 7000 Sequence
Detection Systems, and was quantiﬁed using the HSV-2 Quanti-
tated External Control (Tebu-Bio) [22]. The lower limit of detec-
tion was 300 copies/mL (2.50 log10 copies/mL).
Cervical swabs were tested for Neisseria gonorrhoeae and
Chlamydia trachomatis, using PCR (Amplicor CT/NG PCR
assay; Roche); testing was restricted to swabs dating from
2007 onward, owing to the potential for DNA degradation
[23]. Vaginal smears were examined using wet-mount micros-
copy. Bacterial vaginosis was diagnosed on the basis of the Nu-
gent score assigned to heat-ﬁxed vaginal smears. The presence
of sperm was detected using qualitative PCR to detect the Y
chromosome [24].
The frequency of GUD and HSV-2 shedding and the quan-
tity of HSV-2 DNAwere assessed after stratiﬁcation by ART sta-
tus and ART duration. HIV-1 RNA and HSV-2 DNA loads in
plasma and eCVL specimens were transformed to log10 copies/
mL. Viral suppression was deﬁned as achieving an undetectable
HIV-1 RNA load in plasma (deﬁned as a plasma viral load of
< 2.50 log10 copies/mL) within the ﬁrst 12 months of ART,
and immune reconstitution was deﬁned as a CD4+ T-cell
count increase of ≥100 cells/µL by 12 months after ART initi-
ation [25]; data collected 18 months after ART initiation were
evaluated if data collected at 12 months were missing. Logistic
regression was used to estimate odds ratios (ORs) associated
with (1) detectable shedding and (2) GUD, adjusting for with-
in-woman correlation by using random-effects models. Multi-
variable logistic regression models were constructed using a
hierarchical framework and included factors known to be asso-
ciated with either GUD or detectable cervicovaginal HSV-2,
namely age group [10, 26] and immune reconstitution [27,
28], or to be independently associated with GUD or HSV-2
DNA in univariable analysis, with a P value of <.10. Immune
reconstitution and viral suppression were preferentially includ-
ed in the ﬁnal model owing to missing values for concurrent
CD4+ T-cell counts and plasma viral load.
For the quantitative analyses, visits with undetectable HIV-1 or
HSV-2 were assigned half the threshold value [18]. Random-
effects linear regression was used to assess factors associated with
the quantity of cervicovaginal HSV-2 DNA, restricted to visits
with detectable HSV-2. A multiple linear regression model was
constructed in the same fashion as the logistic model. Statistical
analyses were performed using Stata, version 12.0 (StataCorp).
RESULTS
Between 2003 and 2011, 317 women seropositive for HIV-1 and
HSV-2 were enrolled, of whom 236 had data collected on cervi-
covaginal HSV-2, and 81 did not have any stored samples. The
characteristics of women with shedding data are shown in Sup-
plementary Table 1. The median age at cohort enrollment was 32
years (interquartile range [IQR], 18–48 years); 14% [33 of 236])
were receiving ART at their ﬁrst visit during which HSV-2 DNA
was measured, 54% (128 of 236) initiated ART during the study
period, and 4% (10 of 236) did not have any HSV-2 DNA mea-
sured after starting ART. The median CD4+ T-cell count was 357
cells/µL (IQR, 196–564 cells/μL) at the ﬁrst visit with HSV-2
DNA sampling and 177 cells/µL (IQR, 116–233 cells/μL) at
ART initiation. The most common ART regimen was zidovu-
dine/lamivudine/efavirenz (42%); 85% (130 of 151) achieved
plasma HIV-1 suppression by 12 months of treatment, and
69% (104 of 151) achieved immune reconstitution.
Shedding was measured during 1896 cohort visits, with 1308
occurring during ART. There was a median of 11 visits (IQR, 1–
16 visits) per woman during ART and 6 visits (IQR, 1–16 visits)
per woman before ART initiation. The median follow-up time
was 1.2 years (IQR, 0.2–1.7 years) before ART initiation and 6.2
years (IQR, 5.0–6.6 years) during ART; 48 visits at which
women received valacyclovir were excluded from analyses.
HSV-2 DNA was detected at least once in eCVL samples
from 42% of women (99 of 236) at 8.2% of cohort visits (151
of 1848), with GUD detected concomitantly in 15% of shedding
episodes (22 of 151). Of women with a measurement while not
receiving ART, 33% (67 of 203) had detectable HSV-2 DNA at
15% of visits (84 of 551), and 32% (48 of 151) had detectable
HSV-2 DNA at 5% of visits (67 of 1297; P < .001) after ART ini-
tiation (Table 1). The highest proportion of visits with shedding
732 • JID 2016:213 (1 March) • Low et al
 at London School of H
ygiene &
 Tropical M
edicine on February 22, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Table 1. Variables Associated With the Presence of Cervicovaginal Herpes Simplex Virus Type 2 (HSV-2) DNA and Genital Ulcer Disease (GUD) AmongWomen Living With Human Immunodeficiency Virus Type
1 (HIV-1) in Burkina Faso
Characteristic
HSV-2 DNA Presence GUD Presence
Visits,
Proportion (%)
(n = 1848)a
OR (95% CI)b Regression Coefficientc (95% CI)
Visits,
Proportion (%)
(n = 2809)a
OR (95% CI)b
Unadjusted
P
Value Adjusted
P
Value Unadjusted
P
Value Adjusted
P
Value Unadjusted
P
Value Adjusted
P
Value
Age, yd
18–24 25/204 (12.3) 1.0 1.0 0 0 35/443 (7.9) 1.0 1.0
25–34 78/874 (8.9) 0.58 (.28–1.18) 0.81 (.33–2.02) 0.09 (−.44 to .62) 0.38 (−.21 to .98) 70/1316 (5.3) 0.67 (.37–1.20) 0.53 (.23–1.22)
≥35 48/767 (6.3) 0.39 (.19–.83) .05 0.61 (.23–1.56) .42 −0.16 (−.73 to .42) .52 0.22 (−.42 to .86) .44 69/1036 (6.7) 0.93 (.52–1.69) .25 0.82 (.36–1.87) .21
ART influencee
ART status
Naive 84/551 (15.3) 1.0 1.0 0 0 82/1176 (7.0) 1.0 1.0
Initiated 67/1297 (5.2) 0.26 (.17–.39) .001 0.34 (.20–.60) .001 −0.51 (−.88 to –.14) .007 −0.02 (−.57 to .53) .94 93/1633 (5.7) 0.72 (.51–1.03) .07 1.13 (.62–2.04) .69
CD4+ T-cell count (per
100 cells/µL
increase)
. . . 0.70 (.61–.81) .001 . . . 0.04 (–.09 to .17) .57 . . . . . . 0.79 (.70–.89) .001 0.86 (.74–1.01) .06
Plasma HIV-1 RNA load
(per log10 copies/
mL) increase
. . . 1.70 (1.41–2.05) .001 . . . 0.25 (.07–.42) .005 0.13 (−.12 to .38) .31 . . . 1.49 (1.23–1.79) .001 . . .
Immune reconstitutionf
No 51/502 (10.1) 1.0 1.0 0 . . . 60/772 (7.8) 1.0 . . .
Yes 62/1111 (5.6) 0.54 (.31–.94) .03 0.68 (.37–1.26) .22 0.04 (−.39 to .47) .22 . . . 93/1517 (6.1) 0.79 (.49–1.27) .33 . . .
Viral suppressiong
No 29/184 (15.8) 1.0 1.0 0 . . . 31/269 (11.5) 1.0 1.0
Yes 78/1374 (5.7) 0.31 (.16–.62) .001 0.32 (.15–.67) .003 0.19 (−.31 to .70) .45 . . . 117/1880 (6.2) 0.45 (.24–.83) .01 0.53 (.25–1.11) .09
Mucosal factore
Abnormal vaginal
discharge
No 89/1421 (6.3) 1.0 1.0 0 . . . 113/2154 (5.3) 1.0 1.0
Yes 62/410 (15.1) 2.96 (2.00–4.38) .001 2.86 (1.75–4.68) .001 0.07 (−.31 to .46) .71 . . . 62/655 (9.5) 1.99 (1.40–2.83) .001 1.63 (.99–2.69) .05
Bacterial vaginosis
No 84/1198 (7.0) 1.0 . . . 0 . . . 92/1771 (5.2) 1.0 1.0
Yes 59/580 (10.2) 1.38 (.94–2.04) .10 . . . −0.12 (–.52 to .28) .57 . . . 74/927 (8.0) 1.60 (1.14–2.26) .007 1.31 (.84–2.05) .23
GUD
No 129/1722 (7.5) 1.0 1.0 0 . . . . . . . . . . . .
Yes 22/108 (20.4) 3.22 (1.80–5.76) .001 2.62 (1.28–5.38) .008 −0.40 (–.94 to .13) .14 . . . . . . . . . . . .
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occurred during the last 6 months preceding ART (17% [19 of
110]; Figure 1) and the ﬁrst 3 months of ART (18% [7 of 38]),
and the proportion signiﬁcantly dropped after 12 months of
ART (3% [36 of 1057]; Ptrend < .001). The proportion of visits
during which GUD was detected also increased and decreased,
during the same periods.
Across all visits, concurrent CD4+ T-cell counts were associ-
ated with a 30% decrease in HSV-2 DNA detected per 100 cells/
µL increase (OR, 0.70; 95% CI, .61–.81), whereas concurrent
plasma HIV-1 loads were associated with a 70% increase per
log10 copies/mL increase (OR, 1.70; 95% CI, 1.41–2.05). ART
use was associated with a substantial reduction in HSV-2 shed-
ding (OR, 0.26; 95% CI, .17–.39). There was a 25% decrease in
the odds of shedding per year of ART after the ﬁrst 12 months
(OR, 0.74; 95% CI, .59–.92). In the multivariable model, HIV
suppression was associated with a reduced odds of HSV-2 shed-
ding (adjusted OR, 0.32; 95% CI, .15–.67; Table 1). Shedding
episodes decreased with age in the univariable analysis, al-
though this relationship was less pronounced after adjustment
for ART (older women being more likely to be receiving ART).
During visits with HSV-2 shedding, the mean quantity of
HSV-2 DNA was 4.47 log10 copies/mL (95% CI, 4.20–4.73;
n = 84) in ART-naive participants and 3.96 log10 copies/mL
(95% CI, 3.70–4.22; n = 67) after ART initiation (regression co-
efﬁcient, −0.51; 95% CI, −.88 to −.14; P = .007; Table 1). Con-
current plasma HIV-1 loads were strongly associated with an
increase in the amount of HSV-2 DNA shed (regression coefﬁ-
cient, 0.25 per log10 increase in PVL; 95% CI, .07–.42). In the
multivariable model, there was weak evidence that concurrent
HIV-1 shedding was predictive of an increased quantity of
HSV-2 DNA (adjusted regression coefﬁcient, 0.39; 95% CI,
−.11 to .89).
There were 317 women with clinical data on GUD during the
study period. GUD was present in 22% of women (65 of 292)
with data prior to ART initiation and in 32% (92 of 192) with
data after ART initiation; among visits, 7.0% (82 of 1176) before
ART initiation and 5.7% (93 of 1633) after initiation revealed
GUD (P = .17). There were concurrent vesicles at 43% of visits
(23 of 124) with ulcers. HSV-2 DNAwas detected at 20% of vis-
its (22 of 108) with GUD present and 7.5% of visits (129 of
1722) without GUD present (P < .001). Overall, there was a
decrease in frequency of GUD episodes with an increase in
concurrent CD4+ T-cell count (OR, 0.79; 95% CI, .70–.89 per
100 cells/µL increase) and an increase with increasing plasma
viral load (OR, 1.49; 95% CI, 1.23–1.79 per log10 copies/mL
increase). There was an increase in the odds of GUD during
the ﬁrst 3 months of ART (OR, 2.00; 95% CI, .96–4.20) but an
overall reduction in the odds of GUD during ART (OR, 0.72;
95% CI, .51–1.03). In the multivariable model, there was weak
evidence that GUDwas inversely associated with HIV-1 suppres-
sion (adjusted OR, 0.53; 95% CI, .25–1.11) and with increasing
CD4+ T-cell count (adjusted OR, 0.86; 95% CI, .74–1.01).Ta
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DISCUSSION
We describe the impact of ART on cervicovaginal HSV-2 and
GUD presence over several years. The frequencies of HSV-2
shedding and GUD increased in the 6 months prior to ART ini-
tiation, were sustained at that level for the ﬁrst 3 months of
ART, and decreased thereafter. This differs from ﬁndings
from a study in Uganda, where there was a rise in the frequen-
cies of HSV-2 shedding and GUD during the ﬁrst 3 months of
treatment [13]. In our study, the most substantial decrease in
shedding was seen after 12 months of ART, although we were
limited by the small number of samples in the ﬁrst 3 months.
The effect of ART was associated with HIV-1 suppression
and immune reconstitution, although the magnitude of the ef-
fect was larger for viral suppression. This further supports the
synergistic interactions between HIV-1 and HSV-2 replication,
where systemic HIV-1 replication might drive HSV-2 replica-
tion in the sacral ganglia, compounded by weak immune
control [29–31]. This reduction was maintained over time and
was independent of age; therefore, it is less likely to be due only
to the natural history of HSV-2 [9]. Among women who shed,
HSV-2 DNA quantities were correlated with quantities of gen-
ital HIV-1 RNA, providing additional proof of local direct viral
interactions [32].
The effect of ART on GUD appears to be driven by systemic
HIV-1 suppression, although there was a decrease in the frequen-
cy of GUD among women with higher CD4+ T-cell counts and a
trend toward a reduction in the odds of GUD among women with
immune reconstitution during ART. The slightly different dynam-
ics for the effect of ART on GUD, compared with HSV-2 shed-
ding, suggest that the clinical beneﬁts might wane over time.
This is one of the ﬁrst studies to demonstrate prolonged sup-
pression of HSV-2 shedding during ART; other studies have
shown no change in shedding during ART but reductions in
GUD [33, 34]. The variations in results are likely due to smaller
Figure 1. Frequency of genital herpes simplex virus type 2 (HSV-2) shedding and genital ulcer disease (GUD) among human immunodeficiency virus (HIV)–positive high-risk
women before and after antiretroviral therapy (ART) initiation.
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sample sizes and variable duration of follow-up, particularly if
studies are limited to early periods after ART initiation.
There are limitations to this study. The frequency of sampling
was every 3–6 months, and therefore clinical and asymptomatic
episodes of HSV-2 activation might have been missed. GUD
was assumed to be caused mainly by HSV-2 in this population,
based on studies from the region [35, 36].Our prior study in this
population showed that 52% of GUD cases harbored lesional
HSV-2 DNA [7]. Although we only detected HSV-2 DNA at
20% of visits with concurrent GUD, this is consistent with
other studies that used more sensitive methods [10, 37].
In conclusion, ART has a signiﬁcant inﬂuence on HSV-2 shed-
ding and GUD episodes, primarily associated with HIV-1 sup-
pression. Following ART initiation, HSV-2 shedding is rapidly
suppressed, and the inﬂuence of ART is sustained over time.
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